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Paraoxonase-1 (PON1; EC 3.1.8.1) is an 
enzyme that has three important known 
functions: an anti  oxidative function in pre-
venting the formation of oxidized lipopro-
teins (Shih et al. 1998), a hydrolytic function 
on the active metabolites of some organo-
phosphate insecticides (e.g., paraoxon and 
diazoxon) and other xenobiotic substrates 
(van Himbergen et al. 2006), and a hydrolytic 
function that degrades quorum sensing factors 
of Pseudomonas aeruginosa, thereby increas-
ing host resistance to the bacteria (Ozer et al. 
2005; Stoltz et al. 2008). PON1 is synthe-
sized primarily in the liver and is secreted into 
the blood, where it is associated with high-
density lipoproteins (HDLs) (Costa et al. 
2005; Deakin et al. 2002; James and Deakin 
2004; Sorenson et al. 1999). PON1 belongs 
to a family of calcium-dependent lactonases/ 
hydrolases that also include PON2 and PON3 
(Gaidukov et al. 2006). The three enzymes 
hydrolyze aromatic and long-chain aliphatic 
lactones, but PON2 and PON3 lack paraoxo-
nase (POase; phosphotriesterase) and aryl-
esterase (phenyl acetate hydrolysis) activities 
(Costa et al. 2005). Lactones, such as those 
formed from the enzymatic and non  enzymatic 
oxidation of arachidonic acid and docosa-
hexaenoic acid, are the endogenous substrates 
of PON1 (Draganov et al. 2005). PON1’s 
physiologic activity is thought to be that of 
a lipo  lactonase whose activity results in the 
prevention of athero  sclerosis (Gaidukov et al. 
2006). PON1 prevents the formation of oxi-
dized low-density lipo  proteins (LDLs) and 
protects phospholipids in HDLs from oxida-
tion (Costa et al. 2005).
The PON1 gene contains a variety of 
single-nucleotide polymorphisms in the pro-
moter and the coding sequences (Chen et al. 
2005). Previously, the PON1Q192R polymor-
phism in the coding sequence was thought to 
influence susceptibility to cardiovascular dis-
ease (CVD) (Costa et al. 2005). The PON1192 
polymorphism affects PON1’s hydro  lytic 
activity toward several non  physiologic sub-
strates and thus was thought to influence its 
ability to protect against LDL oxidation. The 
Q alloform was believed to be more protec-
tive of cardio  vascular health than the R allo-
form because it had a greater capacity to 
metabolize oxidized lipids (Costa et al. 2005). 
However, a meta-analysis of 43 published 
studies revealed only a very weak association 
of the PON1192 polymorphism with coro-
nary heart disease (Wheeler et al. 2004) and 
concluded the association was of uncertain 
signifi  cance. Gaidukov et al. (2006) reported 
that the R alloform of PON1 bound HDL 
with a higher affinity than did the Q alloform 
and thus exhibited increased stability and lipo-
lactonase activity. Bhattacharyya et al. (2008) 
found patients with the QQ genotype had an 
increased incidence of major cardiac events. 
Others have reported no association of PON1 
genotype with CVD (Gardemann et al. 2000; 
Ombres et al. 1998). Thus, the association, 
if any, of the PON1192 polymorphism with 
athero  sclerosis remains uncertain. Other stud-
ies have shown an association of lower POase 
activity with athero  sclerotic diseases (Ayub 
et al. 1999; Jarvik et al. 2000; Mackness et al. 
2001), thus demonstrating the importance 
of determining the phenotype (i.e., actual 
enzyme activity or enzyme concentration) and 
not just the genotype when studying athero-
sclerosis. Therefore the continued investiga-
tion of both genotype and phenotype in more 
populations at risk of CVD is warranted.
Plotting the rates of diazoxon hydro  lysis 
[diazoxonase (DZOase)] versus paraoxon 
hydrolysis (POase) (i.e., DZOase/POase ratio) 
separates individuals into three functional 
geno  types of PON1 activity: PON1192QQ, 
PON1192QR, and PON1192RR (Richter and 
Furlong 1999). However, both genotype and 
phenotype (i.e., overall PON1 activity) are 
important for determining the relationship of 
PON1 polymorphisms with susceptibilities to 
disease, sensitivity to organophosphate insec-
ticides, and pharmaco  kinetic status of drug 
metabolism (Richter et al. 1999). Because aryl-
esterase activity, using phenyl acetate as the 
substrate instead of the more toxic organophos-
phates as substrates, is frequently monitored as 
an index of PON1 activity, we also determined 
arylesterase activity in this study.
The significance of PON1 to cardio  vascular 
health and sensitivity to organophosphate 
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Ba c k g r o u n d: The southern United States (excluding Florida) has the highest age-adjusted rate of 
cardio  vascular disease (CVD) in the country, with African Americans having a higher prevalence of 
CVD than Caucasians. Paraoxonase-1 (PON1), an enzyme associated with high-density lipoprotein 
particles, participates both in the hydrolysis of oxidized lipids (thus protecting against athero-
sclerosis) and in the hydrolysis of organophosphates. Higher paraoxonase activity has been associ-
ated with lower risk of atherosclerosis.
oBjectives: In this study we characterized the distribution of the functional PON1Q192R poly-
morphisms (PON status as assessed by diazoxonase to paraoxonase ratios) and the PON1 activity 
levels in 200 adult males and females of both races (50 in each race/sex class) from the southern 
United States from commercially obtained blood bank serum samples.
Me t h o d s : We used spectrophotometric methods with serum to determine PON1 status, aryl  esterase 
activities (phenyl acetate hydrolysis), and levels of cotinine and C-reactive protein (CRP).
re s u l t s: African Americans had higher paraoxonase activities but lower diazoxonase activities than 
did Caucasians, consistent with African Americans having a lower proportion of the functional 
geno  type QQ (QQ 15%, QR 34%, RR 44%, 7% indeterminate), than did Caucasians (QQ 60%, 
QR 31%, RR 7%, 2% indeterminate). Cotinine levels indicated that all samples came from non-
smokers and that CRP levels were higher in African Americans than in Caucasians and higher in 
females than in males. CRP levels showed no association with paraoxonase activities.
co n c l u s i o n s: These data present initial observations for use in characterizing the poorer cardio-
vascular health status of the population in the southern United States and more specifically southern 
African Americans.
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insecticides has been addressed experimentally 
through the use of PON1 knockout mice, 
which were more susceptible to athero  sclerosis, 
had HDL and LDL particles that were more 
susceptible to in vitro oxidation, and had HDL 
particles that were inefficient for hydrolysis 
of oxidized LDL particles in vitro (Shih et al. 
1998). HDL particles isolated from transgenic 
mice with human PON1 had an enhanced 
ability to protect LDL particles from oxidation 
(Tward et al. 2002).
The southern United States (except 
Florida) has higher annual age-adjusted mor-
tality rates from CVD (e.g., coronary heart 
disease and stroke) than do other regions of 
the country (American Heart Association 
2005), and African Americans have higher 
annual age-adjusted mortality rates of CVD 
than do Caucasians. The well-characterized 
critical risk factors for CVD are hyper  tension, 
dys  lipidemias (e.g., high LDL cholesterol and 
low HDL cholesterol), smoking, diabetes 
mellitus, a family history of disease, and obe-
sity. Several theories have been advanced to 
explain the higher stroke mortality rate in the 
South, including low socio  economic status, 
an increased prevalence of severity of hyper-
tension, and the presence of environmental 
toxicants (Perry and Rocella 1998). Data 
on the frequency distribution of PON1192 
genotypes have been reported on numerous 
populations, but not specifically the American 
southern populations, which have the worst 
American health statistics. Previous stud-
ies reported that African Americans have a 
weighted PON1Q192 allele frequency of 0.37 
and a weighted PON1R192 allele frequency 
of 0.63, whereas Caucasians have a weighted 
PON1Q192 allele frequency of 0.73 and 
a weighted PON1R192 allele frequency of 
0.27 (Chen et al. 2003; Scacchi et al. 2003). 
Knowledge of PON1 enzymatic activities as 
related to genotype, phenotype, race, sex, and 
age within a population may provide a use-
ful explanation for some of the disparities in 
CVD among demographic groups.
To characterize the functional genotype 
distribution (as assessed by DZOase/POase 
ratios) and activity levels of PON1 as contrib-
utors to the higher CVD in southern popula-
tions, in the present study we investigated 
PON1 activity levels with three substrates 
(paraoxon, diazoxon, and phenyl acetate) in 
the serum of African-American and Caucasian 
southerners within race, sex, and age groups. 
In addition, we also investigated the lev-
els of the nicotine metabolite cotinine (as a 
possible influence of cigarette smoking on 
PON1 activity and concentrations) (James 
et al. 2000; Nishio and Watanabe 1997) and 
the inflammatory marker C-reactive pro-
tein (CRP), a biomarker for increased risk 
of coronary heart disease (reviewed by Casas 
et al. 2008). Our study samples came from 
a commercial vendor that had obtained 
serum samples from blood banks in Alabama 
and Tennessee. We obtained a total of 200 
serum samples from adult men and women 
in equally distributed race and sex classes 
who self-identified as being Caucasian or 
African American. With the data obtained, 
we observed that African Americans in the 
South have lower DZOase activities, higher 
POase activities, and lower DZOase/POase 
ratios than Caucasians, reflecting the signifi-
cantly different distribution of QQ, QR, and 
RR functional genotypes observed in African 
Americans than that found in Caucasians. 
Our laboratory is expanding these studies at 
present with samples from individuals whose 
cardio  vascular health status is known to deter-
mine what role the difference in frequency 
distribution of QQ, QR, and RR functional 
genotypes and differences in activity levels 
between the racial groups may play in the 
CVD health disparities observed and to inves-
tigate the associations that might exist with 
exposure to environmental chemicals.
Materials and Methods
Chemicals and samples. We purchased 
all biochemicals from Sigma Chemical 
Company (St. Louis, MO). We synthe-
sized paraoxon as described previously by 
Chambers et al. (1990). Diazoxon was pur-
chased from ChemService (West Chester, 
PA). Serum cotinine was determined using 
the Cotinine Direct ELISA (Calbiotech, Inc., 
Spring Valley, CA). Serum CRP was deter-
mined using a high-sensitivity CRP ELISA 
(Calbiotech, Inc.). We purchased serum 
samples from Integrated Laboratory Services-
Biotech (Chestertown, MD), which had 
obtained serum samples from blood banks in 
Alabama and Tennessee. We excluded from 
the study individuals who were < 25 years of 
age or > 65 years of age, who were known or 
suspected to be infected with HIV (human 
immunodeficiency virus) or hepatitis, or who 
did not self-declare as Caucasian or African 
American; no demographic information 
was available on any of the samples other 
than age, sex, and self-declared race. The 
mean ages (± SD) were 33.5 ± 6.9 years for 
African-American females, 40.4 ± 8.5 years 
for African-American males, 39.3 ± 9.2 years 
for Caucasian females, and 36.4 ± 8.5 years 
for Caucasian males. The Institutional Review 
Board for the Protection of Human Subjects 
in Research at Mississippi State University 
approved the study protocol.
POase assay. We measured paraoxon 
hydrolysis spectrophotometrically in micro-
titer plates according to a method described 
by Richter and Furlong (1999). We incu-
bated paraoxon (1.2 mM final concentration; 
stock solution in dry ethanol) in paired serum 
samples of 1 µL serum in a reaction volume 
of 200 µL. A calcium buffer solution of Tris-
HCl (0.1 M, pH 8.0), 2 mM CaCl2, and 
2 M NaCl was used to activate PON1 in one 
set of triplicate samples made from the same 
three independent dilutions of serum. We 
used an EDTA buffer solution with 1 mM 
EDTA instead of CaCl2 to eliminate PON1 
activity in the paired set of triplicate samples 
made from three independent dilutions of 
serum. After mixing and incubation at 37°C 
for 5 min, paraoxon was added, mixed, and 
incubated at 37°C for 20 min with shaking. 
After incubation, the enzyme reactions were 
terminated by adding a solution of 50 µL of 
20 mM EDTA plus 2% Tris base solution in 
deionized water. The 4-nitrophenol released 
was quantified at 405 nm. We subtracted the 
mean of the EDTA triplicates from the mean 
of the CaCl2 triplicates for each individual 
to correct for non-PON1-mediated hydro-
lysis. Data were expressed as micromoles of 
paraoxon hydrolyzed per minute per liter of 
serum. The reaction rate was linear during the 
20-min incubation time.
DZOase assay. We meas  ured the 2-isopropyl- 
4-methyl-6-hydroxypyrimidine (IMHP) 
released from diazoxon hydrolysis spectro-
photometrically in a continuous assay accord-
ing to the method described by Richter and 
Furlong (1999). We incubated diazoxon 
(2.0 mM final concentration; solution in dry 
ethanol) in each sample. Diluted serum (20 µL 
serum plus 1,950 µL of the calcium buffer 
described above) was pre  incubated at 37°C for 
5 min, and then 20 µL diazoxon (2.0 mM final 
concentration) was added. The solution was 
mixed and immediately placed into a cuvette. 
We quantified the IMHP continuously for 
2 min at 270 nm. Samples were run in qua-
druplicate and the values averaged as micro-
moles of diazoxon hydrolyzed per minute per 
liter of serum.
Arylesterase assay. We assessed arylesterase 
activity using phenyl acetate as the substrate. 
We diluted serum to 5 µL/mL in 0.05 M Tris-
HCl plus 2 M NaCl buffer (pH 8.0) contain-
ing either 2 mM CaCl2 to activate PON1 
or 1 mM EDTA to serve as a blank. These 
dilutions (2.5 mL) were warmed to 37°C, and 
then 25 µL of 50 mM phenyl acetate in etha-
nol was added. Absorbance was measured at 
270 nm for 3 min, and the slopes were calcu-
lated. PON1 activity was expressed as micro-
moles of phenyl acetate hydrolyzed per minute 
per liter of serum.
C-reactive protein. Serum CRP was 
quantified spectrophotometrically at 450 nm 
using a high sensitivity CRP ELISA kit (solid-
phase direct sandwich method) following 
the manufacturer’s directions and interpolat-
ing the values from a standard curve. Data 
were expressed as milligrams of CRP per liter 
of serum. We did not include CRP values 
> 10 mg/L in these analyses because these Davis et al.
1228  v o l u m e  117 | n u m b e r 8 | August 2009  •  Environmental Health Perspectives
values are not used in assessing cardio  vascular 
risks (American Heart Association 2005).
Cotinine assay. We quantified serum coti-
nine spectrophotometrically at 450 nm using 
a cotinine ELISA kit following manufacturer’s 
directions. Data were expressed as nanograms 
per milliliter of serum.
Statistical analysis. All data were analyzed 
using the SAS System for Windows (version 
9.1; SAS Institute Inc., Cary, NC). We per-
formed efficacy analyses using a linear mixed 
model (PROC MIXED), and we used the 
least square means when we found statisti-
cal significance to determine the differences 
between groups (race, age groups, and sex) 
with respect to the mean DZOase and POase 
activities. In the mixed models, the fixed 
effects were race, age group, and sex. All sta-
tistical comparisons were two-sided using a 
0.05 significance level.
Results
DZOase and POase activities, and DZOase/
POase ratios. The overall DZOase and POase 
activities for all subjects and for both races are 
shown in Table 1, and the DZOase versus 
POase plots are shown in Figure 1. Similar to 
results of Richter and Furlong (1999), plot-
ting hydrolytic rates separated individuals into 
one of three functional PON1192 genotypes 
for determining PON1 status. The frequency 
distribution of the functional genotypes for 
the entire population was QQ (0.375), QR 
(0.325), and RR (0.255). Nine data points 
(frequency of 0.045) were indeterminate for 
apparent QR and RR genotypes, seven of 
which were from African Americans (three 
females, four males) and two from Caucasians 
(one female, one male); these were not 
included in Figure 1. These nine indetermi-
nate individuals all fell in the region between 
the QR and RR functional genotype. These 
individuals may have nonsense or missense 
mutations as previously described by Jarvik 
et al. (2002).
Differences in race. The frequency dis-
tribution of QQ (0.15), QR (0.34), and RR 
(0.44) functional genotypes within the African-
American population was substantially different 
from the distribution in the Caucasian popula-
tion [QQ (0.60), QR (0.31), and RR (0.07); 
Figure 2]. Caucasians had a 4-fold higher pro-
portion (± 95% confidence interval) for the 
QQ genotype (0.60 ± 0.15) than did African 
Americans (0.15 ± 0.11), and this difference 
was significant. In our study population, 
Caucasians had a PON1192Q allele frequency 
of 0.77 and a PON1192R allele frequency of 
0.23. African Americans had a PON1192Q 
allele frequency of 0.34 and a PON1192R allele 
frequency of 0.66.
The mean DZOase activities of African 
Americans were significantly lower than those 
of Caucasians (p = 3.25–08), whereas the mean 
POase activities of African Americans were 
significantly higher than those of Caucasians 
(p = 6.52–09; Table 1). The mean DZOase/
POase ratio of African Americans was sig-
nificantly lower (p < 0.05) than the ratio of 
Caucasians (Table 1). The racial differences in 
the DZOase activity, the POase activity, and 
the DZOase/POase ratio are all to be expected 
given the differences in the functional 
genotype distributions and the differences 
in the PON1192 allele frequencies observed 
between Caucasians and African Americans 
in our study population. When we compared 
African Americans and Caucasians within the 
same functional genotype, we found no statis-
tically significant differences in mean POase 
and DZOase activities. However, within the 
QQ genotype, we found a non  significant 
trend, with Caucasians having a higher mean 
DZOase activity than African Americans.
Differences in sex and PON1192. The mean 
POase activities of all males and all females 
and the mean DZOase activities of all males 
and all females were not significantly different 
(Table 2). The mean DZOase/POase ratio 
of all males and all females was also not sig-
nificantly different. In addition, we observed 
no differences between sexes in activities and 
the DZOase/POase ratios within each race. 
However, the mean POase activities, the mean 
DZOase activities, and the mean DZOase/
POase ratios were significantly different in 
African-American females compared with 
Caucasian females and in African-American 
males compared with Caucasian males 
(Table 2), again likely reflecting the difference 
in functional genotype distribution between 
the racial groups.
Differences in age and PON1192. We 
separated individuals into three age groups 
(25–30 years, 31–40 years, and > 40 years) for 
statistical analysis. In females, POase activities 
appeared to be higher (p = 0.0366) in the 
youngest group (n = 32) compared with the 
oldest group (n = 32) (Figure 3). The reverse 
appeared to be true in males, with POase 
activities lower (p = 0.0209) in the young-
est group (n = 28) compared with the oldest 
group (n = 45). However, these differences 
are probably the result of uneven sampling of 
functional genotypes among these arbitrary 
age ranges. The females had QQ distribu-
tions of 27%, 47%, and 63% in the youngest, 
middle, and oldest age groups, respectively. 
Conversely, the males had QQ distributions 
of 46%, 32%, and 25% in the youngest, mid-
dle, and oldest age groups, respectively. We 
found no significant differences in DZOase 
activities among the three age groups.
Arylesterase activity. Results plotting   
phenyl acetate hydrolysis (arylesterase activity) 
Table 1. POase and DZOase activities and DZOase/POase ratios in the serum of African-American and 
Caucasian southerners (mean ± SD).
Race   No.  POase activity  DZOase activity  DZOase/POase ratio
All  200  240 ± 144  6,847 ± 2,314  —
African American  100  297 ± 144*  5,973 ± 2,065*  29 ± 24*
Caucasian  100  183 ± 121  7,720 ± 2,227  60 ± 30
Data are expressed as micromoles substrate hydrolyzed per liter of serum.
*p < 0.05 compared with Caucasians.
Figure 1. DZOase activities versus POase activities 
in sera of male and female Caucasian and African-
American southerners, as well as the distribution of 
individuals into three PON1192 functional genotypes 
(QQ, QR, and RR). Abbreviations: AAF, African-
American female; AAM, African-American male; 
CF, Caucasian female; CM, Caucasian male. The 
sample population (n = 191) consisted of 47 AAFs, 
46 AAMs, 49 CFs, and 49 CMs. Results from 3 AAFs, 
4 AAMs, 1 CF, and 1 CF were indeterminate and 
thus were not included in the plot.
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Figure 2. DZOase activities versus POase activi-
ties in sera of male and female Caucasian south-
erners (A) and African-American southerners (B). 
Abbreviations: AAF, African-American female; AAM, 
African-American male; CF, Caucasian female; CM, 
Caucasian male.
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versus POase activity showed a trend toward 
separating individuals into the three func-
tional genotypes (Figure 4), but did not yield 
as clear-cut a distinction among the three 
functional genotypes as did the plot of POase 
versus DZOase. Caucasians had slightly 
higher activities (16,407 ± 341 U/L) than 
African Americans (14,276 ± 327 U/L), but 
this was not statistically significant. 
Cotinine levels. Serum cotinine levels were 
less than the levels indicative of active smokers 
(> 78 ng/mL; Wall et al. 1988) for all samples.
CRP levels. CRP levels were signifi-
cantly higher in African Americans (4.70 ± 
3.50 mg/L) than in Caucasians (3.71 ± 
2.60 mg/L; p < 0.05) and higher in females 
(4.93 ± 3.20 mg/L) than in males (3.53 ± 
2.80 mg/L; p < 0.05), similar to previously 
published data (Lakoski et al. 2006). We 
found no significant association between 
POase and CRP levels or DZOase and CRP 
levels. Individuals with CRP levels > 10 mg/L 
were not included in this analysis because 
CRP levels > 10 mg/L are not considered reli-
able for indicating increased risk of CVD.
Discussion
PON1 plays an important role in hydrolyzing 
many substrates, including oxidized lipids and 
active metabolites of organophosphate insecti-
cides (Chambers 2008). The single-nucleotide 
poly  morphism at position 192 has been pro-
posed to have a significant effect on PON1 
hydrolytic activity, xeno  biotic metabolism, 
and the onset of CVD, with the R alloform 
earlier considered to be associated with vascu-
lar disease (Harel et al. 2004). Despite the fact 
that southerners (except Floridians) in gen-
eral and African Americans in particular have 
higher annual age-adjusted mortality rates 
from CVD than do people in other regions of 
the United States, data on the distribution of 
PON1Q192R in the serum of Caucasians and 
African Americans in the South have not been 
documented. 
In the present study we determined the 
PON1192 functional genotype distribution 
(as assessed by DZOase/POase ratios) and 
PON1 enzymatic activities (paraoxon and 
diazoxon hydrolysis, phenyl acetate hydro-
lysis) in the serum of 200 African-American 
and Caucasian southerners. We assumed that 
the individuals sampled from Alabama and 
Tennessee blood banks were residents of the 
South and therefore representative of south-
erners in general. This study revealed signifi-
cant differences in the functional PON1192 
geno  type distribution between Caucasians 
and African Americans. Caucasians had an 
overwhelmingly higher distribution of the 
functional QQ genotype (60%) than did 
African Americans (15%). Our study agrees 
with results of Chen et al. (2003) and Scacchi 
et al. (2003), who reported that African 
Americans have a higher R allele frequency 
(0.63) and Caucasians have a higher Q allele 
frequency (0.73). However these two studies 
did not report the activity level (pheno  type), 
which is ultimately more important in func-
tional capacity to hydrolyze oxidized lipids. 
The arylesterase activity plot, where phe-
nyl acetate was substituted for diazoxon, did 
not yield as straight  forward a separation of 
functional genotypes as did the paraoxon ver-
sus diazoxon plot. Most laboratories report 
on aryl  esterase activity using phenyl acetate, 
probably because of the high cost, toxicity, 
and instability of diazoxon. However, phenyl 
acetate is not as useful as the toxic organo-
phosphate substrate for characterization of 
PON1 status. Although the African Americans 
had a significantly lower mean DZOase activ-
ity than did Caucasians, the lower activity of 
African Americans with phenyl acetate was 
not statistically significant. Probably because 
of the low numbers after the population was 
divided into functional genotypes, we found 
a trend within the QQ functional genotype 
(not statistically significant) that Caucasians 
had higher DZOase activity; this suggests that 
phenotype is important in characterizing risk 
factors and indicates that more research with 
larger groups of known cardio  vascular health 
status would be useful. 
Much of the difference in DZOase and 
POase activities between the races probably 
resulted from the difference in the PON1192 
geno  type distribution; however, racial dif-
ferences in other genotypic influences (e.g., 
promoter polymorphisms that influence 
expression) and in environmental and lifestyle 
influences, (e.g., diet, statins and other drugs, 
exposure to environmental factors) also prob-
ably contribute to the difference. However, 
the cotinine levels indicated that none of the 
serum samples came from smokers, so smok-
ing was not an influence on the PON1 levels 
measured.
Differences in PON1 activities between 
the sexes have not been shown to be significant 
in other studies (Mueller et al. 1983). Results 
from our study also do not indicate a signifi-
cant difference when comparing DZOase and 
POase activities of females and males separately 
or within each race.
In the present study we found that with 
age, POase activity appeared to decrease 
in females but increase in males, whereas 
DZOase activity did not change significantly 
with age in either sex. The difference in POase 
activity just reaches significance but is likely 
the result of uneven sampling of functional 
genotypes within the various age ranges, as 
mentioned in the “Results.” This interpreta-
tion emphasizes the need to consider potential 
Figure 3. DZOase (A) and POase (B) activities in 
three age classes of male and female southern-
ers. Female age groups: 25–30 years (n = 32), 
31–40 years (n = 36), > 40 years (n = 32); male age 
groups: 25–30 years (n = 28), 31–40 years (n = 
27), > 40 years (n = 45). In (B) within a sex, means 
shown with different lower case letters are signifi-
cantly different (p < 0.05).
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Figure 4. Arylesterase activity as monitored with 
phenyl acetate versus POase activities in sera of 
male and female African-American and Caucasian 
southerners. Abbreviations: AAF, African-American 
female;  AAM,  African-American  male;  CF, 
Caucasian female; CM, Caucasian male. 
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Table 2. POase and DZOase activities and DZOase/
POase ratios in the serum of African-American and 
Caucasian southerners by sex (mean ± SD).
Race/  POase  DZOase  DZOase/
sex  activity  activity  POase ratio
All
  Female  230 ± 154  7,069 ± 2,386  40 ± 32
  Male  250 ± 134  6,023 ± 2,229  41 ± 31
African American
  Female*  300 ± 162  6,289 ± 2,193  31 ± 26
  Male*  295 ± 125  5,657 ± 1,897  26 ± 21
Caucasian
  Female  161 ± 109  7,849 ± 2,335  65 ± 28
  Male  206 ± 129  7,591 ± 2,129  54 ± 32
Data are expressed as micromoles substrate hydrolyzed 
per liter of serum of 50 individuals of each race and sex.
*p < 0.05 for all three values, comparing African-American 
females with Caucasian females and comparing African-
American males with Caucasian males.Davis et al.
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confounders (in this case, functional geno-
type sampling disparities among age classes) 
when drawing conclusions about differences 
in activity levels among groups of individ-
uals. Other studies have shown that serum 
PON1 activity is lower during development 
and at birth but increases over time (Chen 
et al. 2003). PON1 activities have also been 
reported to remain constant during adult-
hood or decrease in elderly subjects (Costa 
et al. 2005; Jarvik et al. 2002; Milochevitch 
and Khalil 2001).
The individuals sampled here did not 
appear to be smokers, as indicated by the low 
cotinine levels. Although we do not know 
whether the blood banks screened out smok-
ers, it would be highly unlikely to obtain 
200 random samples with no smokers among 
them by chance. Because smoking can affect 
PON1 levels, we can assume that this poten-
tial factor did not influence the PON1 activity 
levels measured here. Certainly other xeno-
biotics may have influenced the activity lev-
els, but we had no knowledge of drugs (e.g., 
statins) or environmental chemicals to which 
these individuals may have been exposed.
Although we did not know the health sta-
tus of the individuals in this study, we did 
determine CRP concentrations as a biomarker 
of inflammation and CVD. We did not 
include individuals with CRP levels > 10 mg/L 
in these calculations because recommendations 
of the American Heart Association and the 
Centers for Disease Control and Prevention 
suggest excluding these CRP concentrations 
from clini  cal decisions (Pearson et al. 2003). 
We found that females had higher CRP con-
centrations than did males (p < 0.05) and 
that African Americans had higher CRP con-
centrations than did Caucasians (p < 0.05). 
These results on sex and race are consistent 
with literature reports (Kelley-Hedgepeth et al. 
2008; Lakoski et al. 2006). CRP is influenced 
by modifiable risk factors such as body mass 
index, exogenous estrogen, diabetes, hyper-
tension, smoking, alcohol use, HMG-CoA 
(3-hydroxy-3-methyl  glutaryl-coenzyme A)
reductase inhibitors, aspirin use, physical activ-
ity, LDL, and HDL (Cushman et al. 1999; 
Ridker et al. 1999). However, we have no 
information regarding these factors in our 
study population.
One potential confounder worth noting 
is the potential inaccuracy of the self-identi-
fication of race. Although individuals may be 
primarily one race, in many cases there has 
been racial mixing in the past that may or 
may not be known to the individuals, so the 
racial desig  nation may not have been totally 
accurate.
Conclusions
In this article we report the PON1192 func-
tional genotype distribution, PON1 enzymatic 
activities (POase, DZOase, and aryl  esterase), 
and mean DZOase/POase ratios in the serum 
of African-American and Caucasian south-
erners, along with the CRP and cotinine 
levels of these individuals. Most important, 
we found significant racial differences in the 
PON1192 functional geno  type distribution, 
with African Americans—the race with higher 
CVD—displaying a greater proportion of the 
functional RR geno  type. Although, at present, 
the relationship of the functional genotypes 
to CVD is equivocal, our data support the 
hypothesis that the functional RR genotype is 
less protective of cardio  vascular health. These 
data suggest that further study using sam-
ples of southerners from both races—where 
cardio  vascular health status, lifestyle, and 
environmental influences are known—would 
be of value in characterizing risk of both CVD 
and susceptibility to organophosphate insecti-
cide toxicity. In addition, determining the 
complete PON1 geno  type (i.e., determining 
the promoter and protein poly  morphisms) 
and quantitation of PON1 expression would 
allow the evalua  tion of what factors other 
than geno  type contribute to the differences in 
PON1 activity observed between Caucasians 
and African Americans. Our laboratory is cur-
rently engaged in such a study with southern-
ers of both races and both sexes where the 
presence of CVD and any therapeutic inter-
ventions are known.
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